Document is current
Any future updates will be listed below
-
Authors
Hecker-Nolting, Stefanie
Baumhoer, Daniel
Blattmann, Claudia
Kager, Leo
Kühne, Thomas
Kevric, Matthias
Lang, Susanna
Mettmann, Vanessa
Sorg, Benjamin
Werner, Matthias
Bielack, Stefan S. http://orcid.org/0000-0003-2144-3153
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe
Deutsche Forschungsgemeinschaft
Fördergemeinschaft Kinderkrebs-Zentrum Hamburg
Förderkreis Krebskranke Kinder e.V. Stuttgart
- License Information
-
More Information
Article History
Received: 1 April 2022
Accepted: 15 June 2022
First Online: 18 August 2022
Declarations
:
: Stefanie Hecker-Nolting reports grants from Förderkreis krebskranke Kinder Stuttgart e.V., during the conduct of the study; grants from EISAI, grants from German Childhood Cancer Foundation, outside the submitted work. Leo Kager reports personal fees from Bayer, personal fees from Novartis, personal fees from Amgen, personal fees from Agios, all outside the submitted work. Stefan Bielack reports personal fees from Eli Lilly, personal fees from Ipsen, personal fees from Hoffmann-La Roche, personal fees from Bayer Healthcare, personal fees from Boehringer-Ingelheim, personal fees from EISAI, and personal fees from MAP Biopharma, all outside the submitted work. Daniel Baumhoer, Claudia Blattmann, Thomas Kühne, Matthias Kevric, Susanna Lang, Vanessa Mettmann, Benjamin Sorg, and Mathias Werner do not report any potential conflicts of interest.
